SCHEMBL648934

SCHEMBL648934

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(C(F)(F)F)c(F)c1F)CC1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 4/20 0.40
C5AR1 P21730 1/20 0.38
CRHR1 P34998 4/20 0.35
BCHE P06276 2/20 0.35
ACHE P22303 1/20 0.35
TSHR P16473 3/20 0.33
OPRM1 P35372 2/20 0.33
OPRK1 P41145 2/20 0.33
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
CYP3A4 P08684 2/20 0.33
HSD17B10 Q99714 2/20 0.33
HPGD P15428 1/20 0.33
HDAC1 Q13547 1/20 0.33
UBE2M P61081 1/20 0.33
DCUN1D1 Q96GG9 1/20 0.33
DRD2 P14416 1/20 0.32
DRD3 P35462 1/20 0.32
ALOX15 P16050 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651739 0.94 CCR4 (0.45) CCR4C5AR1CRHR1BCHEACHE
SCHEMBL5137300 0.90 CCR4 (0.49) CCR4C5AR1CRHR1BCHEACHE
SCHEMBL651073 0.88 CCR4 (0.42) CCR4C5AR1CRHR1BCHEACHE
SCHEMBL650740 0.88 C5AR1 (0.39) CCR4C5AR1CRHR1BCHEACHE
SCHEMBL5136106 0.87 C5AR1 (0.41) CCR4C5AR1CRHR1BCHEACHE
SCHEMBL651878 0.86 C5AR1 (0.40) C5AR1CRHR1TSHRKDM4EALDH1A1
SCHEMBL649925 0.86 CCR4 (0.44) CCR4C5AR1CRHR1HDAC1
SCHEMBL651006 0.86 C5AR1 (0.42) CCR4C5AR1CRHR1BCHEACHE
SCHEMBL646859 0.86 C5AR1 (0.39) CCR4C5AR1CRHR1BCHEACHE
SCHEMBL648158 0.86 C5AR1 (0.41) C5AR1CRHR1TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed